Sunshine Biopharma (SBFM) Income towards Parent Company (2011 - 2026)

Sunshine Biopharma's Income towards Parent Company history runs 14 years deep, the most recent figure standing at -$1.2 million for Q1 2026.

• Quarterly Income towards Parent Company fell 5.43% year-over-year to -$1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.1 million (down 2.69% YoY) and the FY2025 annual result came in at -$6.0 million, down 8.7% from the prior year.
• Income towards Parent Company was -$1.2 million for Q1 2026 at Sunshine Biopharma, up from -$2.2 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$538872.0 in Q2 2022 and bottomed at -$23.5 million in Q4 2022.
• A 5-year average of -$2.6 million and a median of -$1.2 million in 2022 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2022 — Income towards Parent Company slumped 3624.47% — and 2023, when it jumped 94.85%.
• Sunshine Biopharma's Income towards Parent Company stood at -$23.5 million in 2022, then soared by 94.85% to -$1.2 million in 2023, then plunged by 109.77% to -$2.5 million in 2024, then climbed by 14.89% to -$2.2 million in 2025, then jumped by 42.52% to -$1.2 million in 2026.
• Business Quant data shows SBFM's Income towards Parent Company at -$1.2 million in Q1 2026, -$2.2 million in Q4 2025, and -$883820.0 in Q3 2025.